Stay updated on OPTIMISE Clinical Trial: Secukinumab in Psoriasis
Sign up to get notified when there's something new on the OPTIMISE Clinical Trial: Secukinumab in Psoriasis page.

Latest updates to the OPTIMISE Clinical Trial: Secukinumab in Psoriasis page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedAdded Revision: v3.4.2. Removed the prior government funding/status notices; the revision history is updated accordingly.SummaryDifference0.1%

- Check21 days agoChange DetectedSite-wide notice about a lapse in government funding appears and the page shows Revision: v3.4.1; there are no changes to the study's core content, outcomes, or data. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check28 days agoChange DetectedAdded a glossary display option and updated revision metadata to v3.4.0, including a No FEAR Act Data notice. Removed the previous QC update label (Last Update Submitted that met QC Criteria), the older No FEAR Act data text, and the prior revision indicator (v3.3.4).SummaryDifference0.1%

- Check42 days agoChange DetectedRevision: v3.3.4 was added and Revision: v3.3.3 was removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check63 days agoChange DetectedLocations have been reorganized with many new location groupings added (e.g., Brussels Capital, Czech Republic, Kent, Madrid, Valencia, etc.). Several previously listed location groups (e.g., Brussels Capital Locations, BGR Locations, Czech Republic Locations) were removed.SummaryDifference1%

- Check85 days agoChange DetectedRevision label updated to v3.3.2, replacing the previous v3.3.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

Stay in the know with updates to OPTIMISE Clinical Trial: Secukinumab in Psoriasis
Enter your email address, and we'll notify you when there's something new on the OPTIMISE Clinical Trial: Secukinumab in Psoriasis page.